Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) will report Q4 2025 financial results on March 5, 2026 before U.S. market open and will not host a conference call. Management will present at three investor conferences in early March 2026, with live webcasts available on the company’s Investors "Events & Presentations" page.
Replays will be archived on the website for 90 days following each presentation.
Positive
- None.
Negative
- None.
News Market Reaction – TNGX
In the Feb 18 session, TNGX declined 3.05%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Conference participation | Neutral | +5.1% | Guggenheim biotech summit fireside chat webcast announcement. |
| Jan 08 | CEO transition | Neutral | -6.2% | Founding CEO retirement and appointment of new President and CEO. |
| Jan 05 | Board appointment | Neutral | -0.2% | Addition of experienced CFO Sung Lee to Board of Directors. |
| Dec 17 | Conference presentation | Neutral | -2.0% | Corporate presentation at 44th J.P. Morgan Healthcare Conference. |
| Nov 26 | Conference participation | Neutral | +1.8% | Piper Sandler healthcare conference fireside chat and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference and management headlines have produced mixed, generally modest price reactions, suggesting limited but variable trading impact from similar news.
Over the past few months, Tango’s news flow has centered on conferences and leadership changes. Participation in events like the J.P. Morgan Healthcare Conference on Jan 14, 2026 and the Piper Sandler conference on Dec 3, 2025 saw small positive and negative moves. The CEO transition on Jan 8, 2026 drew a sharper negative reaction, while the Feb 3, 2026 Guggenheim summit notice was followed by a gain. Today’s earnings-date and conference announcement fits this pattern of largely informational catalysts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences:
TD Cowen 46th Annual Health Care Conference, Boston
- Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ET
- Webcast link here
Barclays 28th Annual Global Healthcare Conference, Miami
- Hosting 1x1 meetings on Tuesday, March 10
2026 Leerink Partners Global Healthcare Conference, Miami
- Fireside chat on Wednesday, March 11 at 3:00-3:30 PM ET
- Webcast link here
The live webcast for each event will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
